FDA Wants To Hear From Afib Patients

Mar 3
AFib News Blog
FDA Wants To Hear From Afib Patients

Posted by Mellanie at StopAfib.org on March 3,  2017  9:46am EST

The FDA is holding Listening Sessions in order to learn more from those with atrial fibrillation. These will be held by the FDA’s Center for Devices and Radiological Health. This is the part of the FDA involved in approving and regulating devices used in treating afib.



For these listening sessions, they are looking for anyone with afib to share your experiences being diagnosed and treated with medications and/or procedures. They also want to understand how you made your procedure decisions and what impact your treatments have had on your quality of life. They will provide you with the questions beforehand so you can come prepared.




These one hour small group teleconferences will take place on the following dates and times and will be filled on a first-come first-served basis (US patients only):



  • Monday, March 13th 2:00 PM ET (1 CT/12 MT/11 PT)

  • Wednesday, March 15th 2:00 PM ET (1 CT/12 MT/11 PT)

  • Wednesday, March 29th 2:00 PM ET (1 CT/12 MT/11 PT)

If you are interested and willing to participate, please email FDAPatientRepProgram@fda.hhs.gov to the attention of Andrea Furia-Helms.



Thanks for your help.

**This blog post reflects the opinion of the author and does not necessarily reflect the opinions of the AHA**



4 Comments
  • zippy
    zippy,
    Done~!  Happy to participate~!Zippy
  • Thumper2
    Thumper2,

    Again, why are we getting these out-of-date notices?? 

    Thumper2 (Judy)

  • MellanieSAF
    MellanieSAF,

    Judy,

    We have been slammed with spammers on the blogs for the past week and are working on a solution. Please be patient as we work through getting the solution in place. The spam post above has been removed.

    Mellanie

  • Thumper2
    Thumper2,

    Thanks, Mellanie, for explaining this.  I'm sorry you have to bother with such spam.

    Thumper2 (Judy)

dark overlay when lightbox active
Back to top